- Diabetes, Obesity and Metabolism
- Association of Protein Z with Prediabetes and Type 2 Diabetes
-
Yun-Ui Bae, Ji Hong You, Nan Hee Cho, Leah Eunjung Kim, Hye Min Shim, Jae-Hyung Park, Ho Chan Cho
-
Endocrinol Metab. 2021;36(3):637-646. Published online June 2, 2021
-
DOI: https://doi.org/10.3803/EnM.2021.962
-
-
6,053
View
-
160
Download
-
3
Web of Science
-
5
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Type 2 diabetes mellitus (T2DM) is a progressive metabolic disease. Early detection of prediabetes is important to reduce the risk of T2DM. Some cytokines are known to be associated with T2DM. Therefore, we aimed to identify cytokines as novel biomarkers of glucose dysmetabolism.
Methods The first stage of the study included 43 subjects (13 subjects with newly diagnosed T2DM, 13 with prediabetes, and 16 with normoglycemia) for cytokine microarray analysis. Blood samples of the subjects were assessed for 310 cytokines to identify potential indicators of prediabetes. The second stage included 142 subjects (36 subjects with T2DM, 35 with prediabetes, and 71 with normoglycemia) to validate the potential cytokines associated with prediabetes.
Results We identified 41 cytokines that differed by 1.5-fold or more in at least one out of the three comparisons (normoglycemia vs. prediabetes, normoglycemia vs. T2DM, and prediabetes vs. T2DM) among 310 cytokines. Finally, we selected protein Z (PROZ) and validated this finding to determine its association with prediabetes. Plasma PROZ levels were found to be decreased in patients with prediabetes (1,490.32±367.19 pg/mL) and T2DM (1,583.34±465.43 pg/mL) compared to those in subjects with normoglycemia (1,864.07±450.83 pg/mL) (P<0.001). There were significantly negative correlations between PROZ and fasting plasma glucose (P=0.001) and hemoglobin A1c (P=0.010).
Conclusion PROZ levels were associated with prediabetes and T2DM. We suggest that PROZ may be a promising biomarker for the early detection of prediabetes. Further large-scale studies are needed to evaluate the relationship and mechanism between PROZ and prediabetes and T2DM.
-
Citations
Citations to this article as recorded by
- On the human health benefits of microalgal phytohormones: An explorative in silico analysis
Angelo Del Mondo, Annamaria Vinaccia, Luigi Pistelli, Christophe Brunet, Clementina Sansone Computational and Structural Biotechnology Journal.2023; 21: 1092. CrossRef - Role of F-box WD Repeat Domain Containing 7 in Type 1 Diabetes
Sarah W. Mohammed, Zainab M. Qassam, Ekhlass M. Taha, Nameer M. Salih Ibn AL-Haitham Journal For Pure and Applied Sciences.2023; 36(3): 167. CrossRef - Identification of Protein Z as a Potential Novel Biomarker for the Diagnosis of Prediabetes
Seung-Hoi Koo Endocrinology and Metabolism.2021; 36(3): 572. CrossRef - Association of Protein Z with Prediabetes and Type 2 Diabetes (Endocrinol Metab 2021;36:637-46, Yun-Ui Bae et al.)
Ji Hong You, Yun-Ui Bae, Ho Chan Cho Endocrinology and Metabolism.2021; 36(5): 1149. CrossRef - Association of Protein Z with Prediabetes and Type 2 Diabetes (Endocrinol Metab 2021;36:637-46, Yun-Ui Bae et al.)
Tiffany Pascreau, Maia Tchikviladze, Emilie Jolly, Sara Zia-Chahabi, Bertrand Lapergue, Marc Vasse Endocrinology and Metabolism.2021; 36(5): 1147. CrossRef
- Diabetes
- Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance
-
Eugene Han, Nan Hee Cho, Seong-Su Moon, Hochan Cho
-
Endocrinol Metab. 2020;35(2):480-483. Published online June 24, 2020
-
DOI: https://doi.org/10.3803/EnM.2020.35.2.480
-
-
5,452
View
-
123
Download
-
5
Web of Science
-
5
Crossref
-
Abstract
PDFPubReader ePub
- We investigated proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations in individuals with normoglycemia, impaired fasting glucose (IFG), and impaired glucose tolerance (IGT). This was a pilot, cross-sectional study including 92 individuals who had not been diagnosed with or treated for diabetes. We measured PCSK9 levels in three groups of subjects; namely, normoglycemia (n=57), IFG (n=21), and IGT (n=14). Individuals with IFG and IGT showed higher PCSK9 concentrations than those in the normoglycemic group, with the highest serum PCSK9 concentrations found in individuals with IGT (55.25±15.29 ng/mL for normoglycemia, 63.47±17.78 ng/mL for IFG, 72.22±15.46 ng/mL for IGT, analysis of variance P=0.001). There were no significant differences in high- or low-density lipoprotein cholesterol among groups. Serum PCSK9 levels are increased in patients with prediabetes compared to subjects with normoglycemia.
-
Citations
Citations to this article as recorded by
- Mediation effect of metabolic factors and inflammation on the association of serum uric acid with serum proprotein convertase subtilisin/kexin type 9 levels
Wen Guo, Qin Cui, Zhenzhen Fu, Qun Zhang, Jue Jia Journal of Clinical Lipidology.2024;[Epub] CrossRef - PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model
Yang Yang, Yeying Wang, Yuwen Wang, Tingyu Ke, Ling Zhao PeerJ.2024; 12: e17676. CrossRef - Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond
Thomas Grewal, Christa Buechler International Journal of Molecular Sciences.2022; 23(3): 1070. CrossRef - Insight into the Evolving Role of PCSK9
Mateusz Maligłówka, Michał Kosowski, Marcin Hachuła, Marcin Cyrnek, Łukasz Bułdak, Marcin Basiak, Aleksandra Bołdys, Grzegorz Machnik, Rafał Jakub Bułdak, Bogusław Okopień Metabolites.2022; 12(3): 256. CrossRef - Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis
Susanne Feder, Reiner Wiest, Thomas S. Weiss, Charalampos Aslanidis, Doris Schacherer, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler Lipids in Health and Disease.2021;[Epub] CrossRef
- Clinical Characteristics of Patients with Adrenal Insufficiency in a General Hospital
-
Ye Yeon Lee, Nan Hee Cho, Jong Won Lee, Nam Kyung Kim, Hye Soon Kim, Mi-Kyung Kim
-
Endocrinol Metab. 2017;32(1):83-89. Published online February 28, 2017
-
DOI: https://doi.org/10.3803/EnM.2017.32.1.83
-
-
5,224
View
-
62
Download
-
6
Web of Science
-
6
Crossref
-
Abstract
PDFPubReader
- Background
Adrenal insufficiency (AI) is a life-threatening disorder caused by the deficiency of adrenal steroid hormones. This retrospective cross-sectional study investigated the characteristics of patients with AI in Korea. MethodsAll consecutive patients with suspected AI who received care at a tertiary referral center in Korea in 2014 and underwent adrenocorticotropic hormone stimulation or insulin-tolerance testing were identified through a review of medical charts. Patients diagnosed with AI were enrolled. Their demographic, clinical, and treatment details were extracted. ResultsOf 771 patients with suspected AI, 183 (23.7%) received a definitive diagnosis. The most common reason for testing was the presence of suspicious AI-related symptoms (30.0%), followed by a history of steroid medications (23.5%). Their mean age was 66.7 years, and females predominated (67.8%). The most common symptoms were general weakness, anorexia, arthralgia, and fever. Approximately half (53.6%) had a history of steroid use. Hydrocortisone was the most common treatment (71.6%), with most patients taking a 30 mg dose (44.2%). The most common dose frequency was twice a day (78.6%). Fourteen patients were treated for adrenal crisis (n=10, 5.5%) or an intercurrent illness (n=4, 2.2%). ConclusionAI may have been caused by steroid medication use in many of the patients included in this study. The detection of AI can be improved by careful history-taking and being alert to the possibility that a patient has used steroids.
-
Citations
Citations to this article as recorded by
- Risk of Mental Illnesses in Patients With Hypopituitarism: A Nationwide Population-Based Cohort Study
I-Hua Wei, Chih-Chia Huang Psychiatry Investigation.2022; 19(6): 418. CrossRef - The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events
Bradley D. Menz, Jacinta L. Johnson, Davina F. Gillard, William Chong, Michael B. Ward Journal of Pharmacy Practice.2021; 34(3): 386. CrossRef - Clinical and biochemical factors to predict biochemical adrenal insufficiency in hospitalized patients with indeterminate cortisol levels: a retrospective study
Worapaka Manosroi, Natapong Kosachunhanan, Pichitchai Atthakomol BMC Endocrine Disorders.2020;[Epub] CrossRef - Possible adrenal insufficiency among fatigue patients in a psychosomatic medical clinic
Sunao Matsubayashi, Nobuhiro Nakatake, Takeshi Hara Endocrine Journal.2020; 67(1): 53. CrossRef - Encountering COVID-19 as Endocrinologists
Eun-Jung Rhee, Jung Hee Kim, Sun Joon Moon, Won-Young Lee Endocrinology and Metabolism.2020; 35(2): 197. CrossRef - Glucocorticoid management of adrenal insufficiency in the United Kingdom: assessment using real-world data
Kamran Iqbal, Kate Halsby, Robert D Murray, Paul V Carroll, Robert Petermann Endocrine Connections.2019; 8(1): 20. CrossRef
|